Multitargeted tyrosine kinase inhibitor stimulates expression of IL-6 and activates JAK2/STAT5 signaling in acute myelogenous leukemia cells

Leukemia. 2009 Dec;23(12):2304-8. doi: 10.1038/leu.2009.163. Epub 2009 Aug 13.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Drug Delivery Systems / methods
  • Humans
  • Interleukin-6 / biosynthesis
  • Janus Kinase 2 / metabolism
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / metabolism
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinase Inhibitors / therapeutic use
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • STAT5 Transcription Factor / metabolism
  • Signal Transduction / drug effects

Substances

  • Interleukin-6
  • Protein Kinase Inhibitors
  • STAT5 Transcription Factor
  • Protein-Tyrosine Kinases
  • Janus Kinase 2